Explore innovative treatments for relapsed follicular lymphoma, focusing on novel therapies that enhance patient outcomes and ...

Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

November 3, 2010 — A new drug for relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma — brentuximab vedotin (developed by Seattle Genetics and Millennium/Takeda) — is close to ...

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma Eligible ...

Danish drugmaker Genmab and its U.S. partner AbbVie said on Friday that their drug for a type of blood cancer failed to ...

Please provide your email address to receive an email when new articles are posted on . Pre-transplant immune checkpoint inhibitors improved survival in relapsed Hodgkin lymphoma compared with ...

Sponsored advertising content is provided by Genmab A/S and AbbVie and does not necessarily reflect the views of CURE Each person’s experience with follicular lymphoma (FL) is unique. Whether you’re ...

Non-transplant salvage therapy for low-risk relapsed/refractory pediatric classical Hodgkin lymphoma (cHL) had high rates of progression-free (PFS) and overall survival (OS) at 3-5 years, three ...

AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...